On Tuesday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was -3.97% drop from the session before settling in for the closing price of $24.66. A 52-week range for NAMS has been $8.90 – $26.35.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -28.76%. When this article was written, the company’s average yearly earnings per share was at 2.05%. With a float of $42.86 million, this company’s outstanding shares have now reached $82.47 million.
Considering the fact that the conglomerate employs 29 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 99.95%, operating margin of -495.6%, and the pretax margin is -534.64%.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward NewAmsterdam Pharma Company NV stocks. The insider ownership of NewAmsterdam Pharma Company NV is 53.61%, while institutional ownership is 40.60%. The most recent insider transaction that took place on Nov 18 ’24, was worth 834,440. In this transaction 10% Owner of this company sold 33,273 shares at a rate of $25.08, taking the stock ownership to the 11,778,760 shares. Before that another transaction happened on Nov 15 ’24, when Company’s 10% Owner sold 8,530 for $25.02, making the entire transaction worth $213,436. This insider now owns 11,812,033 shares in total.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 2.05% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
You can see what NewAmsterdam Pharma Company NV (NAMS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.61.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Compared to the last year’s volume of 0.28 million, its volume of 0.78 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 79.98%. Additionally, its Average True Range was 1.09.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 83.81%, which indicates a significant increase from 81.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.08% in the past 14 days, which was higher than the 50.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.82, while its 200-day Moving Average is $19.49. Nevertheless, the first resistance level for the watch stands at $24.42 in the near term. At $25.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.71. If the price goes on to break the first support level at $23.13, it is likely to go to the next support level at $22.57. Should the price break the second support level, the third support level stands at $21.84.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
There are 92,386K outstanding shares of the company, which has a market capitalization of 2.19 billion. As of now, sales total 14,090 K while income totals -176,940 K. Its latest quarter income was 29,110 K while its last quarter net income were -16,650 K.
